TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.

Authors

Scott T. Tagawa

Sandra and Edward Meyer Cancer Center, New York, NY

Scott T. Tagawa , Daniel Peter Petrylak , Petros Grivas , Neeraj Agarwal , Cora N. Sternberg , Chris Hernandez , Peggy Siemon-Hryczyk , Trishna Goswami , Yohann Loriot

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.

First Author: Scott T. Tagawa

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).

First Author: Scott T. Tagawa

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Safety analysis by UGT1A1 status of TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).

First Author: Yohann Loriot

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy.

First Author: Gurudatta Naik